top of page

SEC Filings

8K

August 8, 2023

8K

August 7, 2023

8K

August 2, 2023

8K

August 1, 2023

8K

July 31, 2023

10K

July 18, 2023

8K

July 17, 2023

On July 14, 2023, Russell Lawrence, President and a member of the United State Antimony Corporation (the “Company”) Board of Directors, resigned from the Company and from the  Board of Directors for personal reasons. Mr. Lawrence also resigned as the Company’s President.  Mr. Lawrence’s resignation is effective as of July 14, 2023.  

8KA

July 17, 2023

In the Form 8-K filed on May 9, 2023, the Company announced the appointment of an eighth director, Dr. Corby G. Anderson, effective on that date.  Upon further review, it has been determined that the articles of incorporation set the maximum number of directors at seven (7).

 

Accordingly, the Company has determined that the appointment of Dr. Anderson was not effective and the appointment has been rescinded.

8K

May 9, 2023

United States Antimony Corporation is pleased to announce the addition of Dr. Corby G. Anderson as an independent director to its board.

8K

April 18, 2023

Company’s third-party independent auditors require additional time to perform audit procedures, complete related testing and review financial statements and other information for the Form 10-K. Management anticipates filing its Form 10-K at the earliest possible date.

8K

March 6, 2023

Department of Defense (“DOD”) and the Defense Logistics Agency (“DLA”) have approved the third and final sample of antimony trisulfide supplied by the company. 

10Q

September 30, 2022

10K

March 31, 2022

DEF 14A

June 9, 2022

bottom of page